Fig 2. Tet2 knockdown does not promote Nras^G12D/+-induced CMML.

(A) Summary of KRAS, NRAS, TET2, ASXL1, EZH2 and NCSTN mutation status in 5 human CMML patients. The percentages of mutant alleles are shown in parentheses. (B–D) Bone marrow cells from control or Nras^G12D/+ mice were infected with retrovirus encoding control or Tet2 shRNA and transplanted into lethally irradiated recipient mice. (B) Kaplan-Meier survival curves of different groups of recipient mice were plotted against days post-transplant. P values were determined by the Log-rank test. (C) Splenomegaly in different groups of recipient mice.. (D) Quantification of donor-derived myeloid cells in peripheral blood of moribund mice. The percentages of monocytes (Mac1⁺ Gr1⁻) and neutrophils (Mac1⁺ Gr1⁺) are indicated in their corresponding quadrants. The results are presented as mean ± standard deviation. Red font indicates significant changes compared with recipients transplanted with control cells infected with control (Ctr) shRNA. Asterisks indicate significant changes compared with recipients transplanted with Nras^G12D/+ cells infected with Tet2 shRNA. * P<0.05; *** P<0.001. BM, bone marrow; N.S., not significant; CMML, chronic monomyelocytic leukaemia; WBC, white blood cell